ORIC Pharmaceuticals, Inc. (ORIC) NASDAQ
7.62
-1.36(-15.14%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
7.62
-1.36(-15.14%)
Currency In USD
| Previous Close | 8.98 |
| Open | 8 |
| Day High | 8.31 |
| Day Low | 7.41 |
| 52-Week High | 14.93 |
| 52-Week Low | 7.23 |
| Volume | 4.02M |
| Average Volume | 1.9M |
| Market Cap | 788.8M |
| PE | -5.48 |
| EPS | -1.39 |
| Moving Average 50 Days | 9.64 |
| Moving Average 200 Days | 10.81 |
| Change | -1.36 |
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
GlobeNewswire Inc.
Jan 12, 2026 1:30 PM GMT
Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
GlobeNewswire Inc.
Dec 06, 2025 1:00 AM GMT
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no si